« Pfizer on a Mission to Grow Pipeline | Main | Pipelines Emptying, Costs Rising, What's Big Pharma To Do? »

07/26/2011

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b01539030f6dd970b

Listed below are links to weblogs that reference Convergence of Biosimilar and Big Pharma Competitors is Natural Order:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Terry McCormick

As you note, this could be expected given the competitive market situation we see now. But it is amazing to me that it took so long to be "topical". Back in 2004, I was advising one of the top two pure biotech firms to get ready for that competition. My point was that traditional Big Pharma HAD to shift to biotech to survive. They did not see that as a threat, feeling their lead and expertise could not be matched...

The thing then as now is the economics. A simple graphic I used then is still relevent: http://www.randdreturns.com/converts-to-big-biopharma/ This is why firms like BMS have completely reinvented themselves towards biotech R&D.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

April 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada